The combined DCR was 0.92 (95%CI: 0.91–0.94, P < 0.05), and RET-TKIs had a significant benefit on the DCR of RET fusion gene-positive NSCLC (Fig. 6). The gene discussed is RET; the disease is non-small cell lung carcinoma.